soul trial oral semaglutide cardiovascular outcomes 2024 2025 results Updates in Medicine on X: "SOUL (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in soul trial oral semaglutide cardiovascular

Comparison of cystatin C and creatinine as predictors of cardiovascular events in a community-based elderly population

Thats a meaningful benefit, since diabetes roughly doubles a persons risk of heart disease

For deg som sammenligner operatrer, er det nyttig sjekke flgende nkkelpunkter: mobilopplevelse, spillbibliotek, bonuser, lojalitetsprogram, kampanjekalender og kundesttte

10.3969/j.issn.1672-7851.2013.10.002 44 GentilellaR.PechtnerV.CorcosA.ConsoliA

Many people taking Ozempic or other GLP-1 medications may not eat enough, and studies have found that their diets often lack important nutrients, including iron